Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Follow-Up Questions
Who is the CEO of Affymax Inc?
Mr. Jonathan Couchman is the President of Affymax Inc, joining the firm since 2014.
What is the price performance of AFFY stock?
The current price of AFFY is $0.0009, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Affymax Inc?
Affymax Inc belongs to N/A industry and the sector is N/A
